JAK2 and graft versus host disease: In the post-transplant setting, JAK2 signaling promotes expansion of alloreactive CD4+ and CD8+ T cells, upregulates MHC class II expression on antigen-presenting cells (APCs), and enhances CXCR3-mediated chemotaxis, collectively sustaining GVHD propagation [8,9].